Every 8-K that Equillium, Inc. (EQ) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow EQ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EQ filings page.
Equillium, Inc. reported second quarter 2026 results and highlighted progress on EQ504, its aryl hydrocarbon receptor modulator for autoimmune and inflammatory diseases. A Phase 1 proof-of-mechanism study in healthy volunteers in Australia is expected to start in the fourth quarter of 2026, with topline data anticipated about six months later. IND-enabling work also began for EQ504 as an inhaled therapy for inflammatory lung diseases and for EQ302 in celiac disease, and a Clinical Advisory Board was established to guide the EQ504 ulcerative colitis program.
Cash and cash equivalents were $57.2 million at June 30, 2026, compared with $61.3 million at March 31, 2026, and $30.3 million at December 31, 2025; the company believes this cash can fund planned operations into 2029. Second quarter 2026 research and development expense was $2.8 million versus $4.1 million a year earlier, while general and administrative expense was $2.4 million versus $2.1 million. Net loss for the quarter was $4.7 million, or $(0.04) per share, compared with $5.7 million, or $(0.16) per share, in 2025. Total assets were $58.7 million and stockholders’ equity was $56.0 million at June 30, 2026.
Equillium, Inc. reported results of its 2026 Annual Meeting of Stockholders. Shareholders holding 54,287,329 shares, or 85.86% of the 63,226,556 shares outstanding as of April 1, 2026, were present or represented by proxy.
Stockholders elected Charles McDermott and Bruce Steel as Class II directors to serve until the 2029 annual meeting. Former director Peter Colabuono was not renominated, and the board size was reduced from seven to six directors.
Shareholders approved an amendment allowing a potential reverse stock split of the common stock at a ratio between 1-for-2 and 1-for-20, to be implemented at the board’s discretion. They also approved increasing authorized common shares from 200,000,000 to 400,000,000 and ratified Crowe LLP as independent auditor for the year ending December 31, 2026.
Equillium, Inc. reported first quarter 2026 results and highlighted progress on its immunology pipeline, led by EQ504. For the quarter ended March 31, 2026, net loss was $5.3 million, or $(0.06) per share, improving from a net loss of $8.7 million, or $(0.24) per share, a year earlier as operating expenses declined.
Research and development expenses fell to $3.0 million from $5.9 million, mainly due to winding down prior clinical studies, while general and administrative expenses declined to $2.6 million from $2.9 million on lower legal and professional fees. Cash and cash equivalents increased to $61.3 million as of March 31, 2026 from $30.3 million at year-end 2025, helped by a $35 million private placement completed in March.
The company expects its cash position to fund currently planned operations into 2029. Equillium plans to start a Phase 1 proof-of-mechanism study of EQ504 in mid-2026, with data anticipated about six months later, and is also evaluating further advancement of its EQ302 program.
Equillium, Inc. reported fourth quarter and full-year 2025 results showing a shift to a development-stage model focused on its EQ504 program. Full-year 2025 revenue was $0 compared with $41.1M in 2024, reflecting the conclusion of prior Ono-related revenue.
Research and development expenses fell sharply to $12.8M from $37.4M, and general and administrative expenses declined to $10.8M from $11.9M. Despite lower operating costs, the full-year net loss widened to $22.4M, or $(0.39) per share, versus a $8.1M loss, or $(0.23) per share, in 2024, mainly because revenue dropped.
Cash, cash equivalents and short-term investments were $30.3M as of December 31, 2025, up from $22.6M a year earlier. Together with a $50M private placement announced in August 2025 and a $35M private placement in March 2026, the company believes it can fund planned operations into 2029. Equillium plans to initiate a Phase 1 proof-of-mechanism study of EQ504 in mid-2026, with data expected about six months later.
Equillium, Inc. entered into a private placement with RA Capital Healthcare Fund to raise approximately $35.0 million through common stock and a pre-funded warrant. The company will sell 1,179,508 shares at $1.854 per share and a pre-funded warrant for up to 17,698,593 shares at $1.8539 per warrant share, with an exercise price of $0.0001 per share. The warrant is exercisable immediately on a cash or cashless basis, subject to a beneficial ownership cap of 19.99%. Equillium plans to use the net proceeds, together with existing cash, to fund development of EQ504 and for working capital and general corporate purposes. The company will also grant the investor registration rights to resell the shares and warrant shares, subject to potential cash penalties if registration obligations are not met.
Equillium, Inc. furnished an 8‑K announcing financial results for the third quarter ended September 30, 2025, via a press release attached as Exhibit 99.1. The company states the information under Item 2.02, including the exhibit, is furnished and not deemed filed under Section 18 of the Exchange Act, and it is not incorporated by reference into other SEC filings except as expressly specified by reference.
Equillium, Inc. filed an amended report to update its previously disclosed change in independent auditor. The company confirms that Crowe LLP has now completed its client acceptance procedures and, on October 21, 2025, executed an engagement letter to serve as Equillium’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
The company states that during the two most recent fiscal years ended December 31, 2024 and December 31, 2023, and through October 21, 2025, it did not consult with Crowe on specific accounting treatments, potential audit opinions, or any issues involving disagreements or reportable events under SEC rules.
Equillium, Inc. filed a Form 8-K reporting a letter from independent auditor KPMG LLP dated October 6, 2025. The company states that KPMG reported no disagreements with management on accounting principles, financial statement disclosure, or audit scope, and identified no reportable events as defined under Regulation S‑K. A copy of KPMG's letter is attached as Exhibit 16.1. The filing also notes the Cover Page Interactive Data File is embedded with the Inline XBRL document. The report is signed by Bruce D. Steel, Chief Executive Officer.
Equillium, Inc. has filed a prospectus supplement for an at-the-market offering of shares of its common stock with an aggregate offering price of up to $75,000,000 under its existing Open Market Sale Agreement with LifeSci Capital LLC.
This prospectus supplement updates and expands a prior program that had covered up to $21,950,000 of common stock. Equillium has already sold 1,719,485 shares for aggregate gross proceeds of $0.96 million under the agreement. A legal opinion from Cooley LLP on the validity of the shares is included as an exhibit.
Equillium, Inc. has regained compliance with Nasdaq’s minimum bid price requirement for its common stock. Nasdaq notified the company on August 29, 2025 that it once again meets Listing Rule 5550(a)(2) for continued inclusion on The Nasdaq Capital Market. Equillium had previously received notices in December 2024 and June 2025 that its shares were below the $1.00 per share bid price requirement, with an additional 180-day grace period granted in June. The company met the rule by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days, a condition that was satisfied on August 28, 2025.
Equillium entered a Securities Purchase Agreement to sell 21,814,874 shares at $0.57 and pre-funded warrants to purchase up to 30,816,705 Warrant Shares at $0.5699, raising approximately $30.0 million at the anticipated Initial Closing. The agreement also permits a Milestone Closing to raise up to approximately $20.0 million if specified clinical or dosing milestones occur and a $2.50 VWAP price condition is met or waived by the investors.
Pre-funded warrants are exercisable at $0.0001 per share with net cashless exercise and beneficial ownership limits to restrict post-exercise holdings. The company agreed to file registration statements within 30 days of closings and faces cash penalties for registration failures. Equillium expects the net proceeds from the Initial Closing to extend its cash runway through 2027, is prioritizing development of EQ504, and has not initiated its announced cryptocurrency treasury reserve strategy.
Equillium, Inc. (EQ) filed an 8-K reporting an amendment to its Open Market Sale Agreement, preliminary cash of approximately $11.5 million as of June 30, 2025, and authorization of a cryptocurrency treasury reserve strategy.
The filing states that on August 3, 2025 the Company replaced Jefferies LLC with LifeSci Capital LLC as sales agent under its ATM Agreement (Amendment filed as Exhibit 10.1). On August 4, 2025 Equillium furnished a press release (Exhibit 99.1) disclosing preliminary, unaudited cash and a strategic expansion to integrate a cryptocurrency treasury reserve strategy; the Company has not purchased any cryptocurrency as of the filing. Equillium expects current cash to fund operations into the fourth quarter of 2025 based on certain assumptions and supplemented its risk factors relating to the crypto strategy (Exhibit 99.2).